AG
BIO icon

Advisor Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Advisor Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1.67M Buy
4,500
+1,945
+76% +$686K 0.01% 907
2019
Q3 		$851K Buy
2,555
+245
+11% +$79.9K 0.01% 1244
2019
Q2 		$722K Buy
2,310
+231
+11% +$69.2K 0.01% 1351
2019
Q1 		$635K Sell
2,079
-1,316
-39% -$355K 0.01% 1421
2018
Q4 		$789K Sell
3,395
-198
-6% -$53.1K 0.01% 1097
2018
Q3 		$1.12M Buy
3,593
+1,547
+76% +$480K 0.01% 907
2018
Q2 		$590K Buy
2,046
+150
+8% +$41.4K 0.01% 1193
2018
Q1 		$475K Buy
1,896
+40
+2% +$10.2K 0.01% 1354
2017
Q4 		$443K Sell
1,856
-256
-12% -$62K 0.01% 1408
2017
Q3 		$470K Buy
2,112
+1,160
+122% +$261K 0.01% 1242
2017
Q2 		$216K Buy
952
+144
+18% +$31.4K ﹤0.01% 1722
2017
Q1 		$162K Sell
808
-18
-2% -$3.47K ﹤0.01% 1822
2016
Q4 		$150K Buy
826
+58
+8% +$9.89K ﹤0.01% 1771
2016
Q3 		$126K Buy
768
+2
+0.3% +$304 ﹤0.01% 1848
2016
Q2 		$108K Buy
+766
New +$109K ﹤0.01% 1879

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Advisor Group's BIO Position: Q4 2019 in Review

Advisor Group increased its Bio-Rad Laboratories Class A (BIO) stake by 76% in Q4 2019, buying an estimated $686K and bringing the position to 4,500 shares worth $1.67M. The position accounts for 0.01% of the portfolio, ranked #907.

Advisor Group first reported a position in BIO in Q2 2016 and has held it in 15 quarters since. 386 funds tracked by Wall St. Rank hold BIO as of Q4 2019.

  • Advisor Group held 4,500 shares of Bio-Rad Laboratories Class A worth $1.67M as of Q4 2019.
  • Advisor Group bought 1,945 Bio-Rad Laboratories Class A shares in Q4 2019, an estimated $686K.
  • Bio-Rad Laboratories Class A made up 0.01% of Advisor Group's portfolio in Q4 2019, its #907 holding.
  • Advisor Group first reported a position in Bio-Rad Laboratories Class A in Q2 2016 and has held it in 15 quarters since.
  • 386 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.